COMPOSITION D'ADJUVANT ANTICANCÉREUX CONTENANT UN PROMOTEUR D'EXPRESSION DE RIP3 EN TANT QUE SUBSTANCE ACTIVE, PROCÉDÉ DE CRIBLAGE D'UN ADJUVANT ANTICANCÉREUX AUGMENTANT LA SENSIBILITÉ À UN MÉDICAMENT ANTICANCÉREUX PAR STIMULATION DE L'EXPRESSION DE RIP3 ET PROCÉDÉ DE SURVEILLANCE DE L'EFFICACITÉ D'UN MÉDICAMENT ANTICANCÉREUX
The present invention relates to a pharmaceutical composition for an anticancer adjuvant containing a receptor-interacting protein kinase-3 (RIP3) protein expression inducing agent or activator as an active ingredient. The present invention also provides a method for enhancing cancer cell death, comprising administering a RIP3 protein expression inducing agent or activator in combination with an anticancer drug to cancer cells. Additionally, the present invention relates to a method for screening an anticancer adjuvant which enhances anticancer drug sensitivity by promoting RIP3 expression； and a method for monitoring anticancer drug sensitivity based on RIP3 expression. Therefore, in the case of patients lacking RIP3 expression, the use of a conventional chemotherapeutic agent after inducing RIP3 expression by pretreatment with a demethylating agent may be an effective therapeutic strategy. Also, it is expected that monitoring anticancer drug sensitivity and screening an anticancer adjuvant that enhances anticancer drug sensitivity in anticancer therapy may be an effective strategy.
